The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 31, 2000
Filed:
May. 04, 1998
George L Kenyon, San Francisco, CA (US);
Margaret Stauber, Germantown, MD (US);
Karl Maurer, Ross, CA (US);
Dolan Eargle, San Francisco, CA (US);
Angelika Muscate, Loerrach, DE;
Andrew Leavitt, San Francisco, CA (US);
Diana C Roe, Newark, CA (US);
Todd J Ewing, San Francisco, CA (US);
Allan G Skillman, Jr, San Francisco, CA (US);
Edward Arnold, Belle Mead, NJ (US);
Irwin D Kuntz, Greenbrae, CA (US);
Malin Young, San Francisco, CA (US);
The Regents of the University of California, Oakland, CA (US);
Rutgers, The University of New Jersey, New Brunswick, NJ (US);
Abstract
The present invention relates to a novel class of compounds that are potent inhibitors of HIV reverse transcriptase and HIV integrase. In addition to being multienzyme inhibitors, the inventive compounds of the present invention are remarkable in at least two other respects. First, they do not appear to be toxic to cells at typical therapeutic concentrations. Second, they appear to be equally effective against mutant strains of HIV reverse transcriptase commonly found in patients who have developed resistance to current reverse transcriptase inhibitors. Because the inventive compounds show promise in combatting viral resistance and are potent inhibitors of both HIV reverse transcriptase and integrase, they are ideal candidates for use in combination with existing therapies or alone in treating AIDS or HIV infection.